This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
mantle-cell-lymphoma
Mantle Cell Lymphoma
Mantle cell lymphoma is aggressive B-cell lymphoma with t(11;14) CCND1-IGH → cyclin D1 overexpression and CDK4/6 → S-phase entry; SOX11+, ATM deletion in ~40%, blastoid variant has TP53 mutations. Ibrutinib/zanubrutinib and venetoclax transformed R/R MCL; CAR-T is approved.
Entry Metadata
| Field | Value |
|---|---|
| ID | mantle-cell-lymphoma |
| Name | Mantle Cell Lymphoma |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507-516. · PubMed 23782157
- Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331-1342. · PubMed 32242358